Loading
Mayo Clinic neuro-oncologist who was lead author of the long-term RTOG 9802 results, which showed that adding PCV chemotherapy to radiotherapy roughly doubles survival in high-risk low-grade glioma.
Jan Buckner is a medical oncologist at Mayo Clinic in Rochester and a long-standing leader of the Alliance for Clinical Trials in Oncology neuro-oncology committee. He was first author of the 2016 New England Journal of Medicine report of RTOG 9802, which showed that radiotherapy followed by procarbazine, lomustine and vincristine lengthened median survival from 7.8 to 13.3 years compared with radiotherapy alone in grade 2 glioma patients who were over 40 or had subtotal resection, changing the standard of care.
| Title | Journal | Year |
|---|---|---|
| RTOG 9802: radiation plus procarbazine, lomustine and vincristine in high-risk low-grade glioma | New England Journal of Medicine | 2016 |
Shares Brain and spinal cord tumours (all types) and the tags brain, trialist.
Shares Brain and spinal cord tumours (all types) and the tags brain, trialist.
Shares Mayo Clinic, Brain and spinal cord tumours (all types) and the tags brain, trialist.
Shares Brain and spinal cord tumours (all types) and the tags brain, trialist.
Shares the tags brain, trialist.
Shares the tags brain, trialist.
Shares Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Astrocytoma, IDH-mutant (grades 2 to 4), Brain and spinal cord tumours (all types).
Shares the tags brain, trialist.